Sandoz to pay Allergan, Duke University $39M over eye drug lawsuit, jury says
Sandoz is on the hook for $39 million to Allergan and Duke University for infringing on their patent for an eyelash-growth drug, Latisse (bimatoprost ophthalmic solution), a Colorado federal jury decided Friday.
In a complaint filed by Allergan and Duke against Sandoz, Allergan said that since its launch in 2016, Sandoz’s generic version of Latisse has caused sales of Allergan’s product to decline by around 50% in Texas. Net sales for Allergan from Latisse were over $70 million annually from its launch in 2009 up to 2018, when the complaint was filed.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.